BRCA1 is an inclusion eligibility criterion in 6 clinical trials for primary peritoneal serous adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA1 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 6 clinical trials for primary peritoneal serous adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA2 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].

TP53 is an inclusion eligibility criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].